Question 1

What role does CGRP play in migraine?

Accepted Answer

CGRP is considered a central mediator of migraine pathophysiology. During migraine attacks, trigeminal sensory neurons release large amounts of CGRP, causing meningeal vasodilation, neurogenic inflammation, and sensitization of pain pathways. Jugular venous CGRP levels rise significantly during attacks and normalize with successful treatment. Crucially, intravenous CGRP infusion can trigger migraine-like headaches in patients with a history of migraine but not in healthy controls, demonstrating a causal role. This understanding directly led to the development of anti-CGRP therapies that have transformed migraine treatment.

Question 2

Why would someone research exogenous CGRP if it causes migraines?

Accepted Answer

CGRP has important protective physiological functions beyond its role in migraine. It is the body's most potent natural vasodilator and plays critical roles in wound healing (promoting keratinocyte proliferation and angiogenesis), cardiovascular protection (ischemic preconditioning, prevention of cardiac hypertrophy), and immune regulation. Research interest in exogenous CGRP focuses on these therapeutic applications. The migraine-triggering effect is specific to individuals with migraine susceptibility and involves pathological sensitization of trigeminal circuits, not a universal response to CGRP.

Question 3

How potent is CGRP as a vasodilator?

Accepted Answer

CGRP is the most potent endogenous vasodilator identified in humans. It is approximately 1000-fold more potent than acetylcholine and 10-fold more potent than prostaglandins on a molar basis. Its vasodilatory effects are long-lasting relative to other vasodilators — a single intravenous dose can produce sustained blood flow increases lasting several hours. This extraordinary potency is why even nanomolar concentrations of CGRP released from sensory nerve endings can produce significant local vasodilation and why CGRP's vascular effects are pharmacologically relevant.

Question 4

What are anti-CGRP therapies and how do they work?

Accepted Answer

Anti-CGRP therapies fall into two categories: monoclonal antibodies that bind and neutralize CGRP itself (fremanezumab, galcanezumab, eptinezumab) or block the CGRP receptor (erenumab), and small-molecule CGRP receptor antagonists called gepants (ubrogepant, rimegepant, atogepant). These represent one of the most significant advances in migraine treatment in decades. They are effective for both acute treatment and prevention of migraine with fewer side effects than older preventive medications. The success of anti-CGRP drugs validates the central role of CGRP in migraine pathophysiology.

Question 5

Does CGRP have wound-healing properties?

Accepted Answer

Yes. CGRP promotes wound healing through multiple mechanisms: it stimulates keratinocyte proliferation and migration, enhances endothelial cell angiogenic activity, modulates local immune cell function (macrophage activation, mast cell degranulation), and increases blood flow to the wound site through vasodilation. Denervated skin heals more slowly, and this delayed healing can be partially rescued by exogenous CGRP application. In diabetic wound models, where neuropathy reduces local CGRP release, supplementation with CGRP has shown accelerated healing in preclinical studies.

Question 6

What is the cardiovascular significance of CGRP?

Accepted Answer

CGRP plays a cardioprotective role through several mechanisms: (1) potent vasodilation reduces cardiac afterload; (2) CGRP mediates ischemic preconditioning — the process by which brief ischemic episodes protect against subsequent severe ischemia; (3) it inhibits pathological cardiac hypertrophy; (4) it promotes coronary vasodilation; and (5) it has anti-inflammatory effects on vascular endothelium. CGRP levels are reduced in hypertension and heart failure. There has been concern that chronic anti-CGRP therapy for migraine might compromise these protective functions, though clinical data has not shown significant cardiovascular adverse events with current anti-CGRP drugs.

Question 7

Is exogenous CGRP safe to administer?

Accepted Answer

Intravenous CGRP infusion has been used in numerous human research studies and is generally well-tolerated in healthy volunteers and cardiovascular research subjects. The primary acute effects are flushing, warmth, and modest decreases in blood pressure due to vasodilation. In migraine-susceptible individuals, CGRP infusion can trigger headache attacks. The protein has a short half-life (~6-10 minutes), so acute vasodilatory effects resolve relatively quickly. Long-term safety data for chronic exogenous CGRP administration does not exist. CGRP is not approved for therapeutic use and is available only as a research reagent.

Question 8

How does CGRP interact with the immune system?

Accepted Answer

CGRP has complex immunomodulatory properties. It promotes mast cell degranulation and histamine release (contributing to neurogenic inflammation), modulates macrophage cytokine production (generally shifting toward anti-inflammatory profiles at physiological concentrations), inhibits dendritic cell antigen presentation, and affects T-cell activation. These immune effects are context-dependent — CGRP can promote acute inflammatory responses (through neurogenic inflammation) while simultaneously providing anti-inflammatory signals to adaptive immune cells. This dual nature makes CGRP's net immune effect highly dependent on the specific tissue, inflammatory context, and concentration.

Question 9

What is the relationship between CGRP and substance P?

Accepted Answer

CGRP and substance P are co-expressed and co-released from the same sensory nerve endings (C-fibers and A-delta fibers) and function cooperatively in neurogenic inflammation. Substance P primarily drives plasma protein extravasation and immune cell chemotaxis, while CGRP provides the vasodilatory component. CGRP also enhances the actions of substance P by inhibiting its enzymatic degradation and potentiating its receptor binding. Together, they constitute the primary effector arm of neurogenic inflammation — the process by which sensory nerves modulate local tissue inflammation independently of immune cell recruitment.

Question 10

Could CGRP be used therapeutically for conditions other than migraine?

Accepted Answer

Several non-migraine applications of CGRP have been explored in preclinical research: diabetic wound healing (restoring neuropeptide-dependent repair mechanisms), Raynaud's disease (vasodilation of constricted digital arteries — CGRP infusion studies showed benefit), pulmonary hypertension (pulmonary vasodilation), and cardiac protection during ischemia-reperfusion injury. CGRP infusion for Raynaud's disease has shown clinical efficacy in small trials. However, CGRP's short half-life, the need for infusion, and the risk of triggering headache in susceptible individuals complicate clinical development. Stabilized analogs or targeted delivery methods may eventually address these limitations.

Origin / Manufacturer	Endogenous
Active Components	CGRP (alpha-CGRP, human)Bacteriostatic water (for reconstitution)
Storage	Lyophilized: -20°C recommended. Reconstituted: 2–8°C
Shelf Life	Lyophilized 12–24 months at -20°C; reconstituted 14 days refrigerated
Form Factor	Lyophilized powder (0.1–0.5 mg vial, research grade)

CGRP

Specifications

Frequently Asked Questions

Related Peptides

BPC-157

LL-37

TB-500 (Thymosin β4 Fragment)

VIP (Vasoactive Intestinal Peptide)